Table 2.
Within group comparisons of health status after TAVR: Iliofemoral group
| TAVR | AVR | ||||||
|---|---|---|---|---|---|---|---|
| Scale/Time Point | n | Paired Difference* (95% CI) | P value | n | Paired Difference* (95% CI) | P value | |
| KCCQ Overall Summary | |||||||
| 1 month | 210 | 21.6 (17.7 to 25.5) | <0.001 | 149 | 3.5 (−1.0 to 7.9) | 0.127 | |
| 6 months | 230 | 25.8 (22.4 to 29.2) | <0.001 | 175 | 24.2 (20.2 to 28.2) | <0.001 | |
| 1 year | 205 | 24.0 (20.6 to 27.5) | <0.001 | 163 | 21.8 (17.5 to 26.0) | <0.001 | |
| KCCQ Physical Limitations | |||||||
| 1 month | 184 | 16.5 (12.0 to 21.1) | <0.001 | 134 | −3.1 (−8.2 to 2.1) | 0.240 | |
| 6 months | 207 | 15.8 (12.1 to 19.6) | <0.001 | 157 | 14.7 (10.1 to 19.2) | <0.001 | |
| 1 year | 178 | 14.8 (10.5 to 19.0) | <0.001 | 154 | 11.1 (6.3 to 15.9) | <0.001 | |
| KCCQ Total Symptoms | |||||||
| 1 month | 209 | 16.7 (13.0 to 20.4) | <0.001 | 148 | 5.2 (0.6 to 9.7) | 0.026 | |
| 6 months | 230 | 21.4 (17.8 to 25.0) | <0.001 | 175 | 21.1 (17.1 to 25.0) | <0.001 | |
| 1 year | 205 | 18.1 (14.5 to 21.7) | <0.001 | 163 | 18.5 (14.2 to 22.8) | <0.001 | |
| KCCQ Quality of Life | |||||||
| 1 month | 207 | 30.3 (26.1 to 34.5) | <0.001 | 147 | 10.2 (5.2 to 15.2) | <0.001 | |
| 6 months | 224 | 36.5 (32.6 to 40.4) | <0.001 | 172 | 32.4 (27.6 to 37.3) | <0.001 | |
| 1 year | 202 | 34.2 (30.4 to 38.0) | <0.001 | 160 | 33.6 (28.9 to 38.2) | <0.001 | |
| KCCQ Social Limitation | |||||||
| 1 month | 166 | 20.8 (15.3 to 26.3) | <0.001 | 119 | −0.7 (−7.8 to 6.4) | 0.853 | |
| 6 months | 187 | 26.5 (21.4 to 31.5) | <0.001 | 142 | 28.4 (22.9 to 34.0) | <0.001 | |
| 1 year | 163 | 25.8 (20.7 to 31.0) | <0.001 | 135 | 23.4 (17.6 to 29.3) | <0.001 | |
| SF-12 Physical Summary | |||||||
| 1 month | 186 | 5.4 (4.0 to 6.9) | <0.001 | 137 | 0.0 (−1.7 to 1.7) | 0.992 | |
| 6 months | 210 | 6.3 (4.8 to 7.8) | <0.001 | 159 | 6.8 (5.3 to 8.3) | <0.001 | |
| 1 year | 187 | 5.9 (4.2 to 7.5) | <0.001 | 147 | 5.1 (3.4 to 6.7) | <0.001 | |
| SF-12 Mental Summary | |||||||
| 1 month | 186 | 3.5 (1.7 to 5.4) | <0.001 | 137 | −2.9 (−5.1 to −0.7) | 0.011 | |
| 6 months | 210 | 5.2 (3.5 to 6.8) | <0.001 | 159 | 2.7 (0.7 to 4.6) | 0.009 | |
| 1 year | 187 | 4.8 (3.0 to 6.5) | <0.001 | 147 | 2.9 (0.9 to 4.9) | 0.004 | |
| EQ-5D Utility | |||||||
| 1 month | 204 | 0.055 (0.024 to 0.087) | <0.001 | 144 | −0.073 (−0.116 to −0.030) | 0.001 | |
| 6 months | 221 | 0.053 (0.023 to 0.082) | <0.001 | 173 | 0.040 (0.014 to 0.065) | 0.003 | |
| 1 year | 199 | 0.043 (0.015 to 0.071) | 0.003 | 155 | 0.003 (−0.029 to 0.035) | 0.870 | |
KCCQ, Kansas City Cardiomyopathy Questionnaire; SF-12, Short Form-12
*
Paired differences reflect changes compared with baseline